Indian Generic Pharma Co. Can't Get $500M Award Nixed

Law360 (May 28, 2020, 5:52 PM EDT) -- A Singapore court has refused to set aside an award issued to a Japanese company that appears to be drugmaker Daiichi Sankyo Co. Ltd. following a soured $4.6 billion deal in which it bought the majority stake in a major Indian pharmaceutical manufacturer.

The judgment issued Thursday, which omitted the names of the parties, rejects two appeals brought by apparent family members of Bhai Singh, founder of Ranbaxy Laboratories Ltd., the manufacturer. It argues that the arbitral tribunal's 2-1 decision in 2016 violated a bar on "punitive, exemplary, multiple or consequential damages" in the arbitration clause.

The timeline of events, award...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!